Coherus Biosciences | CHRS - Себестоимость





Себестоимость Изменить Дата
AbbVie USD 4.29B 73M 2026-06
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.6B 187M 2026-03
Baxter International USD 1.93B 118M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Fujifilm JPY 550.58B 40.74B 2026-03
Gilead Sciences USD 1.44B 174M 2026-03
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Merck USD 2.94B 380M 2026-03
Myriad Genetics USD 63M 1.1M 2025-12
Pacira USD 50.74M 3.89M 2026-03
Perrigo USD 643.7M 103.7M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Teva Pharmaceutical Industries USD 1.98B 30M 2026-06
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03
Xencor USD 61.66M 50.95M 2025-06
Zoetis USD 672M 71M 2026-03